PubRank

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Clinical Trial ID NCT00796445

PubWeight™ 22.99‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00796445

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011 2.89
2 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
3 Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013 2.29
4 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
5 Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis 2011 1.16
6 Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013 1.04
7 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
8 Cancer/testis antigens and urological malignancies. Nat Rev Urol 2012 1.01
9 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
10 What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) 2012 0.88
11 Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLoS One 2014 0.85
12 Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 2010 0.82
13 MAGE-A3-specific anticancer immunotherapy in the clinical practice. Oncoimmunology 2013 0.81
14 Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy. Hum Vaccin Immunother 2014 0.78
15 Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys. J Appl Toxicol 2015 0.78
16 Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 2015 0.78
17 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
18 Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol 2015 0.77
19 Cancer testis antigen and immunotherapy. Immunotargets Ther 2013 0.76
20 Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Ann Oncol 2016 0.75
21 Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology 2016 0.75
Next 100